Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Status: Enrolling
Updated:  12/13/2017
Princess Alexandra Hospital
mi
from
Harlow,
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion
Status: Enrolling
Updated: 12/13/2017
Princess Alexandra Hospital
mi
from
Harlow,
Click here to add this to my saved trials
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/14/2017
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/14/2017
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/14/2017
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/14/2017
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/14/2017
Montefiore Medical Center
mi
from
New York, NY
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/14/2017
Montefiore Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Patient Navigation for Lung Screening at MGH Community Health Centers
Patient Navigation for Lung Screening at MGH Community Health Centers
Status: Enrolling
Updated:  12/14/2017
Massachusetts General Hospital
mi
from
Boston, MA
Patient Navigation for Lung Screening at MGH Community Health Centers
Patient Navigation for Lung Screening at MGH Community Health Centers
Status: Enrolling
Updated: 12/14/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors
A Phase I Study Of PT523 In Patients With Solid Tumors
Status: Enrolling
Updated:  12/14/2017
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors
A Phase I Study Of PT523 In Patients With Solid Tumors
Status: Enrolling
Updated: 12/14/2017
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Colorado Gynecologic Oncology Group
mi
from
Aurora, CO
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Colorado Gynecologic Oncology Group
mi
from
Aurora, CO
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
The Hospital of Central Connecticut
mi
from
New Britain, CT
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Beebe Medical Center
mi
from
Lewes, DE
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Rush University Medical Center
mi
from
Chicago, IL
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Univ of Massachusetts Med School
mi
from
Worcester, MA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
North Shore University Hospital
mi
from
Manhasset, NY
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
North Shore-LIJ Health System CCOP
mi
from
Manhasset, NY
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
North Shore-LIJ Health System CCOP
mi
from
Manhasset, NY
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Riverside Methodist Hospital
mi
from
Columbus, OH
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Mount Carmel Health Center West
mi
from
Columbus, OH
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Mount Carmel Health Center West
mi
from
Columbus, OH
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Cancer Care Associates-Midtown
mi
from
Tulsa, OK
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Cancer Care Associates-Midtown
mi
from
Tulsa, OK
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Abington Memorial Hospital
mi
from
Abington, PA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Lehigh Valley Hospital
mi
from
Allentown, PA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Lehigh Valley Hospital
mi
from
Allentown, PA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Women and Infants Hospital
mi
from
Providence, RI
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
Carilion Clinic Gynecological Oncology
mi
from
Roanoke, VA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
Carilion Clinic Gynecological Oncology
mi
from
Roanoke, VA
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/14/2017
University of Washington Medical Center
mi
from
Seattle, WA
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/14/2017
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated:  12/15/2017
University of Chicago
mi
from
Chicago, IL
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated: 12/15/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated:  12/15/2017
Indiana University Melvin and Bran Simon Cancer Center
mi
from
Indianapolis, IN
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated: 12/15/2017
Indiana University Melvin and Bran Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated:  12/15/2017
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated: 12/15/2017
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated:  12/15/2017
Duke Univeristy Medical Center
mi
from
Durham, NC
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated: 12/15/2017
Duke Univeristy Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated:  12/15/2017
Cleveland Clinic
mi
from
Cleveland, OH
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated: 12/15/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated:  12/15/2017
Oregon Health and Science University
mi
from
Portland, OR
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated: 12/15/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated:  12/15/2017
The Vanderbilt Clinic, Henry-Joyce Cancer Center
mi
from
Nashville, TN
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated: 12/15/2017
The Vanderbilt Clinic, Henry-Joyce Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated:  12/15/2017
SCRI
mi
from
Nashville, TN
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated: 12/15/2017
SCRI
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated:  12/15/2017
BC Cancer Agency
mi
from
Vancouver,
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated: 12/15/2017
BC Cancer Agency
mi
from
Vancouver,
Click here to add this to my saved trials
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated:  12/15/2017
Washington University in St. Louis School of Medicine
mi
from
Saint Louis, MO
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Status: Enrolling
Updated: 12/15/2017
Washington University in St. Louis School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Family Cancer Literacy to Promote Mammography Screening Among Navajo Women
Family Cancer Literacy to Promote Mammography Screening Among Navajo Women
Status: Enrolling
Updated:  12/15/2017
Dine College
mi
from
Shiprock, NM
Family Cancer Literacy to Promote Mammography Screening Among Navajo Women
Family Cancer Literacy to Promote Mammography Screening Among Navajo Women
Status: Enrolling
Updated: 12/15/2017
Dine College
mi
from
Shiprock, NM
Click here to add this to my saved trials
Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women
Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women: Phase 1
Status: Enrolling
Updated:  12/15/2017
Alaska Native Tribal Health Consortium
mi
from
Anchorage, AK
Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women
Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women: Phase 1
Status: Enrolling
Updated: 12/15/2017
Alaska Native Tribal Health Consortium
mi
from
Anchorage, AK
Click here to add this to my saved trials
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors
Status: Enrolling
Updated:  12/15/2017
Local Institution
mi
from
Brussels,
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors
Status: Enrolling
Updated: 12/15/2017
Local Institution
mi
from
Brussels,
Click here to add this to my saved trials
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors
Status: Enrolling
Updated:  12/15/2017
Local Institution
mi
from
Los Angeles, CA
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors
Status: Enrolling
Updated: 12/15/2017
Local Institution
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Biomarker Feedback to Motivate Tobacco Cessation in Pregnant ALaska Native Women: Phase 2
Biomarker Feedback to Motivate Tobacco Cessation in Pregnant ALaska Native Women: Phase 2
Status: Enrolling
Updated:  12/15/2017
Alaska Native Tribal Health Consortium
mi
from
Anchorage, AK
Biomarker Feedback to Motivate Tobacco Cessation in Pregnant ALaska Native Women: Phase 2
Biomarker Feedback to Motivate Tobacco Cessation in Pregnant ALaska Native Women: Phase 2
Status: Enrolling
Updated: 12/15/2017
Alaska Native Tribal Health Consortium
mi
from
Anchorage, AK
Click here to add this to my saved trials
Survival TRaining for ENhancing Total Health (STRENGTH)
A Phase II Randomized Study to Assess the Feasibility of Distance Medicine Based Exercise and Dietary Approaches to Prevent Body Composition Change Occurring During Adjuvant Chemotherapy for Early Stage Breast Cancer
Status: Enrolling
Updated:  12/15/2017
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Survival TRaining for ENhancing Total Health (STRENGTH)
A Phase II Randomized Study to Assess the Feasibility of Distance Medicine Based Exercise and Dietary Approaches to Prevent Body Composition Change Occurring During Adjuvant Chemotherapy for Early Stage Breast Cancer
Status: Enrolling
Updated: 12/15/2017
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Survival TRaining for ENhancing Total Health (STRENGTH)
A Phase II Randomized Study to Assess the Feasibility of Distance Medicine Based Exercise and Dietary Approaches to Prevent Body Composition Change Occurring During Adjuvant Chemotherapy for Early Stage Breast Cancer
Status: Enrolling
Updated:  12/15/2017
Southeastern Medical Oncology Center
mi
from
Goldsboro, NC
Survival TRaining for ENhancing Total Health (STRENGTH)
A Phase II Randomized Study to Assess the Feasibility of Distance Medicine Based Exercise and Dietary Approaches to Prevent Body Composition Change Occurring During Adjuvant Chemotherapy for Early Stage Breast Cancer
Status: Enrolling
Updated: 12/15/2017
Southeastern Medical Oncology Center
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Survival TRaining for ENhancing Total Health (STRENGTH)
A Phase II Randomized Study to Assess the Feasibility of Distance Medicine Based Exercise and Dietary Approaches to Prevent Body Composition Change Occurring During Adjuvant Chemotherapy for Early Stage Breast Cancer
Status: Enrolling
Updated:  12/15/2017
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Survival TRaining for ENhancing Total Health (STRENGTH)
A Phase II Randomized Study to Assess the Feasibility of Distance Medicine Based Exercise and Dietary Approaches to Prevent Body Composition Change Occurring During Adjuvant Chemotherapy for Early Stage Breast Cancer
Status: Enrolling
Updated: 12/15/2017
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Survival TRaining for ENhancing Total Health (STRENGTH)
A Phase II Randomized Study to Assess the Feasibility of Distance Medicine Based Exercise and Dietary Approaches to Prevent Body Composition Change Occurring During Adjuvant Chemotherapy for Early Stage Breast Cancer
Status: Enrolling
Updated:  12/15/2017
Cancer Centers of the Carolinas - Eastside
mi
from
Greenville, SC
Survival TRaining for ENhancing Total Health (STRENGTH)
A Phase II Randomized Study to Assess the Feasibility of Distance Medicine Based Exercise and Dietary Approaches to Prevent Body Composition Change Occurring During Adjuvant Chemotherapy for Early Stage Breast Cancer
Status: Enrolling
Updated: 12/15/2017
Cancer Centers of the Carolinas - Eastside
mi
from
Greenville, SC
Click here to add this to my saved trials
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
The Feasibility and Outcome of Cyberknife® Stereotactic Radiosurgical Boost and Salvage Therapy for Head and Neck Cancer
Status: Enrolling
Updated:  12/17/2017
Boston University Cancer Research Center
mi
from
Boston, MA
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
The Feasibility and Outcome of Cyberknife® Stereotactic Radiosurgical Boost and Salvage Therapy for Head and Neck Cancer
Status: Enrolling
Updated: 12/17/2017
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
A Phase II Study of Intratumoral Injection of Interleukin-12 Plasmid and in Vivo Electroporation in Patients With Merkel Cell Carcinoma
Status: Enrolling
Updated:  12/18/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
A Phase II Study of Intratumoral Injection of Interleukin-12 Plasmid and in Vivo Electroporation in Patients With Merkel Cell Carcinoma
Status: Enrolling
Updated: 12/18/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
A Phase II Study of Radiofrequency Ablation Combined With External Beam Radiation Therapy for Patients With Medically Inoperable Non-Small Cell Lung Cancer (Stage Ia and Select Ib) and the Predictive Value of Positron Emission Tomography
Status: Enrolling
Updated:  12/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
A Phase II Study of Radiofrequency Ablation Combined With External Beam Radiation Therapy for Patients With Medically Inoperable Non-Small Cell Lung Cancer (Stage Ia and Select Ib) and the Predictive Value of Positron Emission Tomography
Status: Enrolling
Updated: 12/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies
Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center
Status: Enrolling
Updated:  12/19/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies
Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center
Status: Enrolling
Updated: 12/19/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  12/19/2017
Arizona Cancer Center at UMC North
mi
from
Tucson, AZ
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 12/19/2017
Arizona Cancer Center at UMC North
mi
from
Tucson, AZ
Click here to add this to my saved trials